Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Rautenberg, Tanja
19  Ergebnisse:
Personensuche X
?
1

Effect on ovarian activity and ovulation inhibition of diff..:

Duijkers, Ingrid J.M. ; Klipping, Christine ; Rautenberg, Tanja...
Contraception.  110 (2022)  - p. 6-15 , 2022
Link: https://doi.org/10.1016/..
 
?
2

The effects on ovarian activity of delaying versus immediat..:

Banh, Camille ; Rautenberg, Tanja ; Duijkers, Ingrid...
Contraception.  102 (2020)  3 - p. 145-151 , 2020
Link: https://doi.org/10.1016/..
 
?
3

A field study into the appropriateness of transcutaneous ul..:

Kauffold, Johannes ; Rautenberg, Tanja ; Hoffmann, Grit...
Theriogenology.  64 (2005)  7 - p. 1546-1558 , 2005
Link: https://doi.org/10.1016/..
 
?
4

Ultrasonographic characterization of the ovaries and the ut..:

Kauffold, Johannes ; Rautenberg, Tanja ; Richter, Andreas..
Theriogenology.  61 (2004)  9 - p. 1635-1648 , 2004
Link: https://doi.org/10.1016/..
 
?
5

Ultrasonographic characterization of the ovaries in non-pre..:

Kauffold, Johannes ; Rautenberg, Tanja ; Gutjahr, Stephan..
Theriogenology.  61 (2004)  7-8 - p. 1407-1417 , 2004
Link: https://doi.org/10.1016/..
 
?
6

Relaxin-like factor (RLF) mRNA expression in the fallow dee:

Hombach-Klonisch, Sabine ; Kauffold, Johannes ; Rautenberg, Tanja...
Molecular and Cellular Endocrinology.  159 (2000)  1-2 - p. 147-158 , 2000
Link: https://doi.org/10.1016/..
 
?
7

A phase III, open label, randomized multicenter controlled ..:

Sehouli, Jalid ; Tomè, Oliver ; Dimitrova, Desislava...
Journal of Cancer Research and Clinical Oncology.  143 (2016)  3 - p. 541-550 , 2016
Link: https://doi.org/10.1007/..
 
?
8

Bevacizumab and platinum-based combinations for recurrent o..:

Pfisterer, Jacobus ; Shannon, Catherine M ; Baumann, Klaus...
http://eprints.gla.ac.uk/217571/7/217571.pdf.  , 2020
Link: http://eprints.gla.ac.uk..
 
?
9

Supplementary Table S5 from Validation of the Clinical Use ..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473459.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
10

Supplementary Table S2 from Validation of the Clinical Use ..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473474.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
11

Supplementary Figure S2 from Validation of the Clinical Use..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473492.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
12

Supplementary Figure S3 from Validation of the Clinical Use..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473486.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
13

Supplementary Figure S4 from Validation of the Clinical Use..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473480.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
14

Supplementary Table S6 from Validation of the Clinical Use ..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473453.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
15

Supplementary Table S1 from Validation of the Clinical Use ..:

Raphaël Leman ; Etienne Muller ; Angelina Legros...
doi:10.1158/1078-0432.24473477.v1.  , 2023
Link: https://doi.org/10.1158/..
 
1-15